Under construction – not a live service
Sign in
Taking people in MalaysiaNo phase

Reduced chemotherapy doses and survival in older people with non-small cell lung cancer

Looks back at chemotherapy dosing and survival in older adults with lung cancer.

Plain-language title generated from the registry record
Registry title: Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations

Key facts

Where
Kota Kinabalu, Kuala Lumpur, and Kuantan, MalaysiaSee the 3 sites

Where in Malaysia

  • Hospital Wanita Dan Kanak-Kanak SabahKota Kinabalu, MalaysiaTaking people
  • Universiti Malaya Medical CentreKuala Lumpur, MalaysiaTaking people
  • Hospital Tengku Ampuan AfzanKuantan, MalaysiaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Malaya
Trial code
NCT07369596
Record updated
2 June 2026
Original description
Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity.Read full original descriptionShow less

Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations: A Retrospective Cohort Study.

Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity.

This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.

Inclusion: Age ≥65 years; Histologically confirmed stage IV NSCLC; Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion; Treated with at least ONE cycle of first-line chemotherapy.

Exclusion: Patients who received targeted therapy or immunotherapy as monotherapy in the first-line setting; Incomplete survival data.

ClinicalTrials.gov NCT07369596